Tran Chau My Thanh | Neuroscience | Young Scientist Award

Posted on by sciencefather

Dr. Tran Chau My Thanh | Neuroscience | Young Scientist Award

Dr. Tran Chau My Thanh, a dedicated researcher at Duy Tan University, Vietnam 🇻🇳, holds a medical degree and Ph.D. from Hue University of Medicine and Pharmacy 🎓. Her work bridges the gap between clinical medicine and molecular biology 🧬. With a strong passion for translational research, she focuses on using bioinformatics and genomic tools for early diagnosis and targeted therapy development for diseases like cancer, diabetes, and cardiovascular disorders 💉. Through CRISPR/Cas9 and RNA networks, she aims to revolutionize patient-specific treatment pathways 🚀. Her extensive lab experience, scholarly publications, and ongoing innovations make her a promising leader in biomedical science 🏅.

Profile

Education 🎓

Dr. Thanh earned her Medical Degree (M.D.) from Hue University of Medicine and Pharmacy 🏥 and went on to complete her Doctorate (Ph.D.) in the same prestigious institution 🎓. Her education was deeply rooted in both clinical and research training, equipping her with a comprehensive understanding of human health and disease 🧠. Throughout her academic journey, she focused on genomics, molecular medicine, and biotechnology 🔬. The rigorous curriculum and hands-on exposure in advanced labs trained her in modern diagnostic tools and therapeutic innovations ⚙️. She also mastered computational biology and molecular interactions, forming a solid foundation for her groundbreaking work in RNA regulation and gene editing technologies such as CRISPR/Cas9 🧪.

Experience 👨‍🏫

Dr. Thanh brings rich experience as a medical doctor and academic at Duy Tan University 🏫. Her research career spans multiple roles in molecular diagnostics, bioinformatics, and therapeutic innovation 🧬. She has led studies on disease biomarkers, participated in international collaborations 🌐, and worked extensively with cell lines, recombinant DNA, and next-gen sequencing data 🔍. Her proficiency in wet lab and dry lab environments empowers her to integrate experimental biology with computational modeling 🧫💻. Alongside mentoring students and publishing SCI-indexed research, she contributes to translational medicine by connecting bench science to bedside applications, helping advance precision medicine for critical illnesses 💡.

Awards & Recognitions 🏅

Dr. Thanh is a nominee for the Young Scientist Award by the International Cognitive Scientist Awards 🧠🏆. Her impactful work on circular RNAs, miRNAs, and disease biomarker networks has garnered international recognition 🌍. She’s been acknowledged in high-impact journals for discoveries related to coronary heart disease and cancer diagnostics 📖. Her scholarly articles are indexed in SCI and Scopus, and she continues to influence the biomedical community through conference presentations, peer reviews, and academic collaborations 🤝. As a rising figure in molecular biology, her research promises transformative outcomes for early disease detection and targeted therapies 🧬✨.

Research Interests 🔬

Dr. Thanh’s research explores circRNA/miRNA/mRNA interactions, protein-protein networks, and gene function analysis 🧬🧠. She is driven by the quest to discover novel biomarkers for early diagnosis of complex diseases such as cancer, stroke, and diabetes 💊. Her focus includes CRISPR/Cas9 gene editing, molecular docking, and simulations for drug discovery and target validation 💻🧪. She also builds interaction networks to map LncRNA/CircRNA/miRNA/gene/protein-drug relationships, contributing to personalized medicine approaches 🎯. Through bioinformatics, she decodes gene expression dynamics and immune infiltrations to enable efficient diagnostics and therapeutics 💡. Her ultimate goal is to bridge computational biology with translational research for global health improvement 🌐💚.

Publications 

1. Hsa_circRNA_0000284 acts as a ceRNA to participate in coronary heart disease progression
by sponging miRNA-338-3p via regulating the expression of ETS1
2. Identification of hsa_circ_0001445 of a novel circRNA-miRNA-mRNA regulatory network as
potential biomarker for coronary heart disease
3. Potential diagnostic value of serum microRNAs for 19 cancer types: a meta-analysis of
bioinformatics data

Yuanyuan Li | Movement Disorder | Best Researcher Award

Posted on by sciencefather

Dr. Yuanyuan Li | Movement Disorder | Best Researcher Award

🧠 Dr. Yuanyuan Li is a dedicated neurologist and researcher specializing in neurodegenerative diseases, particularly Parkinson’s disease and REM sleep behavior disorder. She obtained her Ph.D. in Neurology from Shanghai Jiao Tong University School of Medicine and has been actively involved in cutting-edge research at Ruijin Hospital’s Department of Neurology. As a project leader, she has explored the role of α-synuclein in dopaminergic neurons, investigating its transport pathways and impact on cell viability. Dr. Li has authored multiple high-impact publications in renowned journals such as Neurology and J Neuroinflammation. Her work has contributed significantly to understanding the early biomarkers of neurodegenerative disorders. She has received prestigious awards, including the National Scholarship for Doctoral Students and the Outstanding Graduate Award from Shanghai Jiao Tong University. With numerous conference presentations and accolades, Dr. Li continues to drive forward advancements in neurodegenerative disease research. ✨📚

Profile

Education 🎓

🎓 Dr. Yuanyuan Li completed her Ph.D. in Neurology at Shanghai Jiao Tong University School of Medicine, where she focused on neurodegenerative diseases, particularly Parkinson’s disease and REM sleep behavior disorder. Her doctoral research emphasized the role of α-synuclein in dopaminergic neurons, uncovering its impact on neurodegeneration. Throughout her academic journey, Dr. Li consistently demonstrated excellence, earning the First-Class Academic Scholarship and the Meritorious Student Award. She was recognized as an Outstanding Graduate and received the prestigious National Scholarship for Doctoral Students. Beyond coursework, she actively engaged in translational research, bridging laboratory findings with clinical applications. Her education has provided a strong foundation in neurobiology, molecular neuroscience, and clinical neurology. With a passion for uncovering early biomarkers of neurodegeneration, Dr. Li’s educational background has shaped her into a leading researcher in the field. 📖🧬

Experience 👨‍🏫

Dr. Yuanyuan Li has extensive research experience at Ruijin Hospital’s Department of Neurology, affiliated with Shanghai Jiao Tong University School of Medicine. As a principal investigator, she led the Shanghai Jiao Tong University Doctoral Innovation Fund project, studying α-synuclein’s transport mechanisms in dopaminergic neurons and its effects on cell viability. Her expertise spans biomarker discovery, neuroinflammation, and disease progression in neurodegenerative disorders. She has collaborated on numerous high-impact studies published in Neurology, J Neuroinflammation, and NPJ Parkinson’s Disease. Dr. Li has also presented her findings at major conferences, including the National Neurology Conference and the Oriental Neurology Conference. Her experience in both basic and clinical research allows her to bridge the gap between laboratory discoveries and patient applications, advancing diagnostic and therapeutic strategies for Parkinson’s disease and related disorders. 🏥🧠

Awards & Recognitions 🏅

Dr. Yuanyuan Li has received numerous prestigious awards for her contributions to neurology and neuroscience research. She was awarded the National Scholarship for Doctoral Students, recognizing her academic excellence and groundbreaking research. She also received the Outstanding Graduate Award and the Meritorious Student Award from Shanghai Jiao Tong University. Her outstanding academic performance earned her the First-Class Academic Scholarship, demonstrating her dedication to advancing neurological research. Dr. Li has been recognized for her contributions at major conferences, winning the “Excellent Paper Presentation” award at the Oriental Neurology Conference. Additionally, she secured First Prize for Poster Presentation at the “Bo Ji Yi Yuan” Academic Forum. Her accolades reflect her commitment to advancing our understanding of neurodegenerative diseases, particularly Parkinson’s disease. These honors highlight her as a rising star in the field of neurology. 🏅📜

Research Interests 🔬

🧪 Dr. Yuanyuan Li’s research focuses on neurodegenerative diseases, with an emphasis on Parkinson’s disease, REM sleep behavior disorder (RBD), and α-synuclein pathology. Her work explores the molecular mechanisms driving these disorders, particularly the role of α-synuclein in dopaminergic neurons, its transport pathways, and its impact on cell viability. She has also investigated immune biomarkers, neuroinflammation, and genetic variants associated with Parkinson’s progression. Dr. Li’s studies have contributed to identifying predictive markers for early-stage neurodegenerative diseases, aiding in early diagnosis and potential therapeutic interventions. Through her publications in top journals like Neurology, J Neuroinflammation, and NPJ Parkinson’s Disease, she has advanced knowledge in the field. Her work integrates clinical and experimental neuroscience, bridging gaps between laboratory findings and real-world applications. Dr. Li’s research continues to shape the understanding of neurodegenerative disorders and their early detection. 🧬🔍

 

4Publications 

  • Gene Polymorphisms of Parkinson’s Disease Risk Locus and Idiopathic REM Sleep Behavior Disorder

    Biomedicines
    2025-03-24 | Journal article
    DOI: 10.3390/biomedicines13040788
    CONTRIBUTORS: Min Zhong; Yang Jiao; Aonan Zhao; Mengyue Niu; Jinjun Ran; Jun Liu; Yuanyuan Li

  • Understanding Causal Relationships Between Imaging-Derived Phenotypes and Parkinson’s Disease: A Mendelian Randomization and Observational Study

    Biomedicines
    2025-03-18 | Journal article
    DOI: 10.3390/biomedicines13030747
    CONTRIBUTORS: Yichi Zhang; Min Zhong; Zhao Yang; Xiaojin Wang; Zhongxun Dong; Liche Zhou; Qianyi Yin; Bingshun Wang; Jun Liu; Yuanyuan Li et al.

  • Understanding Causal Relationships between Imaging-Derived Phenotypes and Parkinson’s Disease: A Mendelian Randomization and Observational Study

    2025-02-05 | Preprint
    DOI: 10.20944/preprints202502.0350.v1
    CONTRIBUTORS: Yichi Zhang; Min Zhong; Zhao Yang; Xiaojin Wang; Zhongxun Dong; Liche Zhou; Qianyi Yin; Bingshun Wang; Jun Liu; Yuanyuan Li et al.

  • Network disruption based on multi-modal EEG-MRI in α-synucleinopathies

    Frontiers in Neurology
    2024 | Journal article
    DOI: 10.3389/FNEUR.2024.1442851
    WOSUID: WOS:001304283700001
    CONTRIBUTORS: Wang, Chunyi; Hu, Jiajia; Li, Puyu; Zhang, Ming; Zhou, Liche; Luo, Ningdi; Zhu, Xue; Yin, Qianyi; Zhong, Min; Zhou, Xinyi et al.

Elsa Pittaras | Neuroscience | Women Researcher Award

Posted on by sciencefather

Dr. Elsa Pittaras | Neuroscience | Women Researcher Award

Elsa Pittaras is a Basic Life Research Scientist at Stanford University, specializing in neuroscience, cognition, and sleep research. With expertise in molecular biology, neuroanatomy, pharmacology, and behavior, she has extensively studied decision-making processes in mice. Her research has contributed significantly to understanding sleep deprivation’s effects on cognition and memory in Down Syndrome and Alzheimer’s disease models. She has published multiple papers as both first and last author, showcasing her leadership in neuroscience. Elsa’s goal is to advance research on mood disorders, cognition, and neurochemistry, aspiring to become an independent researcher in the U.S. 🇺🇸🔬🧠

Profile

Education 🎓

Elsa Pittaras earned a B.S. in Physiology from the University of Caen (2010), an M.S. in Neuroscience from the University of Paris Sud and ENS Cachan (2012), and a Ph.D. in Neuroscience from Neuro-PSI and the Biomedical Research Unit of the French Army (2016). Her multidisciplinary foundation in biology, physics, chemistry, and mathematics from Châtelet, Douai (2009) laid the groundwork for her neuroscience expertise. Throughout her education, she focused on decision-making, sleep deprivation, and neurochemical mechanisms in cognition. 🧠📚🎓

Experience 👨‍🏫

Elsa Pittaras has been a Basic Life Research Scientist at Stanford University since 2022, focusing on cognitive enhancement in Down Syndrome and Alzheimer’s disease models. She was a Postdoctoral Fellow at Stanford (2017-2022), investigating sleep and circadian rhythms’ effects on memory. Previously, she conducted research at the Biomedical Research Unit of the French Army (2016-2017) and completed her Ph.D. at Neuro-PSI. Her career includes internships in neuroscience at Neuro-PSI (2011-2012) and clinical observations at CHU Caen (2010). 🏛️🧬🧪

Research Interests 🔬

Elsa’s research explores decision-making, memory, and sleep in neurodevelopmental disorders. She pioneered the Mouse Gambling Task, revealing individual decision-making strategies. Her Ph.D. identified neurochemical markers of decision-making behaviors and the effects of sleep deprivation. At Stanford, she investigates sleep’s impact on cognition in Down Syndrome and Alzheimer’s models, aiming to improve memory and sleep quality through pharmacological interventions. Her work bridges behavioral neuroscience with neurochemistry to enhance cognitive function. 🧠💡🛌

Awards & Recognitions 🏅

Elsa has received prestigious grants, including the Jerome Lejeune Research Grants (2019, 2020), the Fyssen Foundation Research Grant (2017), and travel awards for conferences such as T21RS (2021) and Advances in Sleep and Circadian Science (2019). She was also recognized by the French Society for Research and Sleep Medicine (2014) and received a European Neuroscience Federation travel award (2016). 🏅

Publications 

  • Selectively Blocking Small Conductance Ca2+-Activated K+ Channels Improves Cognition in Aged Mice.

  • Short-term γ-aminobutyric acid antagonist treatment improves long-term sleep quality, memory, and decision-making in a Down syndrome mouse model

  • Behavioral and Neuronal Characterizations, across Ages, of the TgSwDI Mouse Model of Alzheimer’s Disease.

  • Inter-individual differences in cognitive tasks: focusing on the shaping of decision-making strategies

  • Handling, task complexity, time-of-day, and sleep deprivation as dynamic modulators of recognition memory in mice

  • Enhancing sleep after training improves memory in down syndrome model mice

 

Junhui Chen | Stroke | Best Researcher Award

Posted on by sciencefather

Dr. Junhui Chen | Stroke | Best Researcher Award

Chen Junhui, MD, is an Associate Chief Physician and a postdoctoral researcher at Xiangya School of Medicine, Central South University. He has also been a visiting scholar at the University of South Florida (USF), USA. He currently serves as the lead researcher in the Neurosurgery Research Group at the 904th Hospital of the Joint Logistics Support Force. He is a member of the Vascular Group of the Neurosurgery Branch of the Jiangsu Medical Association and the Youth Committee of the Translational Medicine Professional Committee of the Chinese Microcirculation Society. He has been recognised as a “Double Hundred” outstanding young talent in Wuxi.

Profile

Education 🎓

Dr Chen holds a Doctor of Medicine (MD) from Wuhan University and completed his postdoctoral research at Xiangya School of Medicine, Central South University. He has a strong medical background and gained international research experience in neurosurgery as a visiting scholar at USF, USA.

Experience 👨‍🏫

He has participated in five National Natural Science Foundation projects and led eight research projects, including those funded by the Jiangsu Provincial Natural Science Foundation and major military scientific research programmes. Dr Chen has been actively involved in both neurosurgical research and clinical treatment, specialising in endovascular intervention and microsurgical treatment of intracranial aneurysms and ischaemic stroke.

Research Interests 🔬

His research focuses on the mechanisms of neuroinjury in subarachnoid haemorrhage and the clinical and mechanistic study of delirium. Over the past five years, he has published 30 SCI papers, including 10 in top-tier journals classified as Q2 or higher in the Chinese Academy of Sciences, with his findings cited in leading journals such as Stroke.

Awards & Recognitions 🏅

Dr Chen has received numerous prestigious awards, including the Second Prize of the Hubei Provincial Science and Technology Progress Award, the Third Prize of the Military Science and Technology Progress Award, the Wuhan University Academic Innovation Award, and the Outstanding Paper Award at the World Chinese Neurosurgery Conference.

Publications 📚

Jeevitha Gowda R | Cognitive impairment | Best Researcher Award

Posted on by sciencefather

Ms. Jeevitha Gowda R | Cognitive impairment | Best Researcher Award

Assistant Professor, Alliance University, United Kingdom

🧠 Dr. Jeevitha Gowda R is a dedicated research scholar specializing in cognitive neuroscience and public health, with a strong focus on dementia prevention. She has expertise in developing cognitive screening tools, conducting neuropsychological assessments, and designing neuroscience-based interventions to enhance brain health. Currently serving as a Guest Faculty and Research Associate, she is passionate about bridging research with real-world applications. With proficiency in EEG, ERP, and data analysis, her work emphasizes cognitive aging, behavioral psychology, and mental well-being. Her research contributions include multiple conference presentations, publications, and cognitive training programs. She has received prestigious recognitions, including Best Paper Awards and research fellowships. Her commitment extends to community mental health programs, where she collaborates with NGOs and research institutions. Through her work, she aims to advance cognitive neuroscience and improve public health outcomes. 📚🔬

Profile

Education 🎓

🎓 Dr. Jeevitha Gowda R holds a Ph.D. in Cognitive Neuroscience and Public Health from Ramaiah University of Applied Sciences, Bengaluru (Thesis Submitted), focusing on developing cognitive tools for early dementia detection in primary healthcare settings. She earned a Master’s in Cognitive Neuroscience from JSS Academy of Higher Education, Mysuru (2018), ranking among the top 3 students, with coursework in neural cognition, psychological assessment, and clinical interventions. Her dissertation explored mental fatigue due to sleep deprivation using EEG and ERP. She completed her Bachelor’s in Life Sciences from JSS College for Women, Mysuru (2016), excelling in biochemistry, microbiology, and environmental psychology. Additionally, she trained at the Defence Institute of Psychological Studies (DRDO) and Narayana Health, Bengaluru, gaining hands-on experience in EEG, neuropsychological assessments, and cognitive therapy. Her interdisciplinary education combines neuroscience, psychology, and public health, preparing her for impactful research and innovation in brain health. 🧠📖

Experience 👨‍🏫

💼 Dr. Jeevitha Gowda R has extensive experience as a Research Associate at the Centre for Integrative Health and Well-Being (2020–Present), where she develops neuropsychological intervention tools and conducts cognitive behavioral therapy (CBT) programs. She also serves as a Senior Research Associate at Brighter Minds, focusing on cognitive enhancement and neuroscience-based training programs. As a Guest Lecturer at Ramaiah University of Applied Sciences (2021–Present), she teaches biostatistics, neurophysiology, and psychology. Her past clinical internships at DRDO and Narayana Health provided her with hands-on expertise in EEG, ERP, and neuropsychological assessments. She has conducted research on cognitive impairment, dementia screening, and sleep deprivation’s effects on cognition. Additionally, she has authored 50+ neuroscience articles, presented at international conferences, and collaborated with NGOs for mental health awareness. Her diverse experience integrates academic, clinical, and research-based expertise to advance cognitive neuroscience and public health. 🏥📊

Research Interests 🔬

🔬 Dr. Jeevitha Gowda R’s research bridges cognitive neuroscience, psychology, and public health, focusing on early dementia detection, cognitive aging, and neuropsychological interventions. She specializes in developing culturally relevant cognitive screening tools for primary healthcare, improving accessibility to dementia diagnostics. Her work explores neuropsychological assessments, EEG-based cognitive analysis, and behavioral interventions for enhancing mental well-being. She has conducted studies on sleep deprivation, cognitive impairment, and neurofeedback therapy. She collaborates with institutions like DRDO, Narayana Health, and Brighter Minds to implement neuroscience-driven programs. Her research extends to the psychological well-being of dementia caregivers, neurocognitive training for brain health, and integrating technology into mental health solutions. Through interdisciplinary studies and global research collaborations, she aims to advance early dementia detection methods and improve cognitive health strategies. Her work contributes to policy-making, clinical psychology, and public health initiatives. 🏥📊

Awards & Recognitions 🏅

🏆 Dr. Jeevitha Gowda R has received multiple accolades for her contributions to cognitive neuroscience and public health research. She won the Best Paper Award at the Epidemiology Foundation of India Conference (2023, Goa) for her groundbreaking work on dementia screening. Her research paper on cognitive tool validation earned a Special Mention at the International Dementia Conference (DEMCON-2024, IISC Bangalore). During her master’s, she ranked among the top 3 dissertations at JSS Academy of Higher Education. She was awarded the Senior Research Fellowship (SRF) by Ramaiah University of Applied Sciences (2022–2024) for her Ph.D. research. She has also secured research grants for projects on dementia detection and cognitive enhancement. Recognized for her impactful contributions, she collaborates with prestigious institutions, including DRDO and Narayana Health, to advance neuropsychological research. Her work continues to shape innovations in mental health and aging. 🎖️🧠

Publications 📚

  • Jeevitha Gowda R, Anish Mehta, Krishnamurthy Jayanna. (2025).
    Dementia: A Public Health Challenge in India. South Eastern European
    Journal of Public Health, 29–43. Retrieved from
    hps://www.seejph.com/index.php/seejph/article/view/3295 (Scopus)

  • Jeevitha Gowda R. The Impact of Cultural Beliefs and Stigma on
    Dementia Care and Diagnosis: A Scoping Review, 25 November 2024,
    PREPRINT (Version 1) available at Research Square
    hps://doi.org/10.21203/rs.3.rs-5519592/v1
  • Jeevitha Ramesh, Parimala Guruprasad (2024) Factors Affecting the
    Psychological Well-Being of Caregivers of Dementia Patients: A
    Thematic Review. Journal of Neurology Research Reviews & Reports.
    SRC/JNRRR-260
  • Development and Validation of Cognitive Screening Tools for
    Dementia Detection in Primary Care Seings: An Exploratory Pilot
    Study – Under review at International Journal of Geriatric Psychiatry.
    (Corresponding Author)
  • Burden of Cognitive Impairment Including Dementia, and Associated
    Risk Factors Among the Rural Population of South Karnataka, India –
    Under review at Journal of Public Health Research. (Corresponding
    Author)
  • Impact of Training Module on Lifestyle and Healthy Behaviours: An
    Exploratory Pilot in India – Under review at Journal Explore.
    (Co-Author)

Carmela Conte | Neurodegenerative diseases | Best Researcher Award

Posted on by sciencefather

Prof Dr. Carmela Conte | Neurodegenerative diseases | Best Researcher Award

 

Profile

Education

Carmela Conte obtained her Master’s degree in Biological Sciences from the University of Perugia on November 3, 1994. She then pursued a Ph.D. in Medical Embryology through a joint program between the Universities of Perugia and Ferrara, completing it between December 30, 1996, and January 19, 2000. Following this, she specialized in Chemistry and Food Technology at the University of Perugia, earning her specialization between November 1, 2000, and November 1, 2002. Most recently, on September 29, 2023, she received National Habilitation as an Associate Professor in Biochemistry. She currently serves as an Aggregate Professor in her field.

Work experience

Since September 7, 2007, Carmela Conte has been serving as an Aggregate Professor in Biochemistry at the University of Perugia, where she teaches courses in General and Systematic Biochemistry, Medical Applied Biochemistry, and Molecular Biology. In addition to her teaching responsibilities, she participated in a Teaching and Training Mobility Program at VUMC Medical University of Amsterdam from June 24 to July 5, 2019, where she worked on a research project investigating the role of Toll-like receptors in Parkinson’s disease. She has been a member of the European Society for Neurochemistry since 2007 and, since March 17, 2022, has also been affiliated with the International Parkinson and Movement Disorder Society.

Research Activity

Carmela Conte’s research focuses on neurodegenerative diseases, with particular emphasis on animal models, signal transduction, molecular biology, and cell biology. Her specific research topics include the role of Toll-like receptors in Parkinson’s disease, neuroinflammation, synucleinopathies, oxidative stress, and Parkinson’s disease. Since September 7, 2007, she has been actively involved in editorial work, serving as a Reviewer Editor for Frontiers in Neuroscience (Neurodegeneration section) and as an ad hoc reviewer for several journals, including Amino Acids, The Cerebellum, Free Radical Research, Biomolecules, PLOS One, Experimental Gerontology, Molecules, Cells, Neurochemical Research, Neuroscience, Pharmacological Reports, International Journal of Molecular Sciences, Viruses, and the Journal of Biotechnology. Additionally, she has been a Guest Editor for Molecules and Cells, overseeing special issues and topic collections on neurodegenerative diseases. She has presented her research at numerous scientific meetings and conferences, including the 2009 Meeting of the European Society for Neurochemistry in Leipzig, the 2019 European Biotechnology Congress in Valencia, the 2021 European Biotechnology Congress in Sofia, the 2022 National Meeting of the Sphingolipid Club, and the 2023 Meeting of Parkinson’s Disease and Movement Disorders, where she discussed findings related to Toll-like receptor 4, alpha-synuclein accumulation, and sphingomyelinase activity in Parkinson’s disease models.

Publication

Suleyman Yildizdal | Craniosynostosis | Best Researcher Award

Posted on by sciencefather

Dr. Suleyman Yildizdal | Craniosynostosis | Best Researcher Award

 

 

Profile

Education

He completed his education at Org. Kenan Evren School from 2000 to 2008, followed by Gaziantep Anadolu High School from 2008 to 2012. He then pursued his medical training at Hacettepe University Faculty of Medicine from 2012 to 2018. After earning his medical degree, he continued his specialization in Plastic, Reconstructive, and Aesthetic Surgery as a resident at Hacettepe University Faculty of Medicine from November 2018 to February 2024. In April 2024, he joined Ankara Research and Training Hospital, where he continues to work in the Department of Plastic, Reconstructive, and Aesthetic Surgery.

 

Work experience

He has participated in various courses and workshops to enhance his expertise in plastic, reconstructive, and aesthetic surgery. He attended the Resident Ethics Course at Hacettepe University’s Department of History of Medicine and Medical Ethics on January 10-11, 2019. He also completed the 5th Basic Residency School organized by the Turkish Society of Plastic, Reconstructive, and Aesthetic Surgery in Bolu, Turkey, from January 22-25, 2020. Further advancing his skills, he took part in the 15th Advanced Residency School in Antalya, Turkey, from April 20-24, 2023. Additionally, he attended the 1st Cadaver Course of Craniofacial Anomaly and Maxillofacial Surgery at Hacettepe University on September 3-4, 2022, and the 1st Cadaver Course of Orthognathic Surgery at Koc University Hospital in Istanbul, Turkey, on September 7-8, 2022.

In addition to his clinical and surgical training, he has contributed to academic literature by co-authoring book chapters. He co-wrote Age-Related Changes in Trunk Aesthetics in Beauty, Aging, and Anti-Aging (1st ed., Elsevier, 2022) alongside G. G. Üstün and S. Yıldızdal. He also contributed to Dudak ve Damak Yarıkları Hacettepe Ekip Yaklaşım, co-authoring “Apert and Crouzon Syndrome” with İbrahim Vargel.

Awards

He has achieved remarkable academic success, securing 16th place in the National Examination for Specialty in Medicine among over 18,000 participants. Additionally, he ranked 571st in the National Student Selection and Placement Examination out of more than 2 million candidates.

He has actively participated in national meetings within his field, contributing to discussions and advancements in plastic, reconstructive, and aesthetic surgery. He attended the 41st National Turkish Plastic Reconstructive and Aesthetic Surgery Meeting in Samsun, Turkey, from October 26-30, 2019. He also participated in the National Turkish Plastic Reconstructive and Aesthetic Surgery Eastern Mediterranean Meeting on Cleft Lip and Palate, held in Gaziantep, Turkey, from February 7-9, 2020. Furthermore, he attended the 43rd National Turkish Plastic Reconstructive and Aesthetic Surgery Meeting in Antalya, Turkey, from November 10-14, 2021.

 

Publication

Michal Schwartz | Neurodegenerative diseases | Best Researcher Award

Posted on by sciencefather

Prof Dr. Michal Schwartz | Neurodegenerative diseases | Best Researcher Award

Michal Schwartz (born 1 January 1950) is a professor of neuroimmunology at the Weizmann Institute of Science. She is active in the field of neurodegenerative diseases, particularly utilizing the immune system to help the brain fight terminal neurodegenerative brain diseases, such as Alzheimer’s disease and dementia.[3][1]

Schwartz’s studies have shown that the immune system supports a healthy brain’s function and is vital for healing and protecting the brain in case of injury or disease.[4]

Schwartz coined the term protective autoimmunity[5] and discovered roles for immune cells in repair and neurogenesis. She has been the elected chair of the International Society of Neuroimmunology (ISNI) since 2016.[6]

In 2023 Schwartz received the honorary Israel Prize for Life Sciences.

 

Profile

Education

Schwartz gained her Bachelor of Science in chemistry at the Hebrew University of Jerusalem in 1972. She received her Ph.D in Immunology in 1977 at the Weizmann Institute of Science, where she would later spend the majority of her career. She also spent time at the University of Michigan, Ann Arbor, researching nerve regeneration.[when?

 

Work experience

At the Weizmann Institute, she progressed from senior scientist in the Department of Neurobiology to full professor in 1998, and was then awarded the Maurice and Ilse Katz Professorial Chair in Neuroimmunology in 2016.[7] Schwartz’s work in neuroimmunology has encompassed a wide range of pathologies in the central nervous system (CNS), including injury, neurodegeneration, mental dysfunction, and aging. She coined the term protective autoimmunity and demonstrated the role of immune cells such as macrophages and T cells in spinal cord repair. She also identified specific brain areas for ‘cross talk’ between the CNS and the immune system. This cross-talk is important for recruiting immune cells and maintaining a healthy brain, and the disruption of this cross-talk can play a role in brain aging and neurodegenerative disease. She also showed this role in pregnancy and fetal brain development, where immune disruption in the mother can be linked to neurodevelopmental disorders in their children. Another focus of her work has been on repurposing cancer immunotherapies such as PD-1 blockers to treat neurodegenerative disorders, such as Alzheimer’s disease.

Macrophages

The Schwartz team discovered that bone marrow-derived macrophages are needed for central nervous system (CNS) repair. The brain-resident myeloid cells (the microglia), and infiltrating monocyte-derived macrophages are not redundant populations, despite their myeloid phenotype, and display distinct functions in resolution of brain inflammation.[8][9][10]

Autoimmunity

In her research, Schwartz discovered that the ability to cope with sterile CNS injuries requires support in the form of an adaptive immune response mediated by CD4+ T cells that recognize CNS antigens. She coined the concept of protective autoimmunity, to distinguish this response from autoimmune disease, in which the anti-self response escapes control. Over the years, it became clear that adaptive immunity is needed to facilitate the recruitment of immunoregulatory cells, including bone marrow-derived macrophages and FoxP3 regulatory T cells, though the balance between regulatory T cells and effector memory cells is different in the periphery versus the brain.[11][12][13]

Brain Homeostasis

Schwartz’s team discovered the role of adaptive systemic immune cells, and specifically T cells recognizing brain antigens (Protective autoimmune T cells), in supporting the cognitive capacity of the healthy brain, for lifelong neurogenesis, and functional brain plasticity. These observations paved the way for numerous additional discoveries in which the brain-immune axis was described.[14][15][16]

The Choroid Plexus

Schwartz’s team identified the brain’s choroid plexus (CP) within the blood-cerebrospinal fluid barrier as an immunological interface between the brain and the immune system. It serves as a niche that hosts immune cells, and as a physiological entry gate for leukocytes. Focusing on this unique niche within the brain led the Schwartz group to propose that IFN-γ holds the key to regulating CP gateway activity. Her team further showed that in brain aging and neurodegenerative diseases (studied using both mouse models and human samples), dysfunction of this interface is determined both by signals originating in the brain, and signals from the aged immune system, which led to the identification of Type-I Interferon (IFN-I) at the CP as a negative player, affecting the fate of the aging brain in general, and of microglia, in particular. A similar IFN-I signature at the CP was subsequently discovered by others in Alzheimer’s disease and in the postmortem brains of infected patients who died from COVID-19.[17][14][10]

Immunotherapy

The discovery that adaptive immunity plays a key role in brain function and repair, the need for bone marrow-derived macrophages to resolve local brain inflammation, the fact that Alzheimer’s disease (AD) and all forms of dementia are mainly age-related diseases, and the fact that the immune system is particularly affected by aging all led Schwartz to propose a new treatment for combating dementias. Schwartz suggested empowering systemic immunity, using a form of immunotherapy by modestly blocking the inhibitory immune checkpoint PD1/PD-L1 pathway.[citation needed] This treatment drives an immune-dependent cascade of events, that allows the harnessing of bone marrow-derived macrophages and regulatory T cells to help clear toxic factors from the diseased brain, and to arrest the local inflammation, thereby providing a comprehensive multi-factorial therapy through modification of multiple elements that go awry in AD. Schwartz’s patents for developing such immunotherapy for AD are licensed to a small Biopharma company, Immunobrain Checkpoint. The company is awaiting a clinical trial in AD patients, supported in part by the National Institute of Aging, the US National Institutes of Health, and The Alzheimer’s Association.[18][19][20][21][22][23]

Publication

1. Rachmian N, Medina S, Cherqui U, Akiva H, Deitch D, Edilbi D, Croese T, Salame T, Peralta Ramos
J, Cahalon L, Krizhanovsky V, Schwartz M. 2024. Senescent microglia conserved in aging and
Alzheimer’s disease exhibit elevated TREM2 protein levels. Nat Neurosci 27: 1116-24
2. Tsitsou-Kampeli A, Suzzi S, Kenigsbuch M, Satomi A, Strobelt R, Singer O, Feldmesser E, Purnapatre
M, Colaiuta SP, David E, Cahalon L, Hahn O, Wyss-Coray T, Shaul Y, Amit I, Schwartz M. 2023.
Cholesterol 24-hydroxylase at the choroid plexus contributes to brain immune homeostasis. Cell Rep
Med: 101278
3. Suzzi, S. Croese T., Ravid A., Gold O., Clark A., Medina A., Kitsberg D., Adam M., Vernon K., Kohnert
E., Shapira I., Malitsky S., Itkin M., Brandis A., Mehlman T., Salame T., Colaiuta S., Cahalon L.,Slyper
M., Greka A., Habib N., Schwartz M. 2023. N-acetylneuraminic acid links immune exhaustion and
accelerated memory deficit in diet-induced obese Alzheimer’s disease mouse model 2023. Nat. Commun.
14:1293.
4. Kenigsbuch M, Bost P, Halevi S, Chang Y, Chen S, Ma Q, Hajbi R, Schwikowski B, Bodenmiller B, Fu
H, Schwartz M*, Amit I* (equal contribution, and corresponding authors). 2022. A shared diseaseassociated oligodendrocyte signature among multiple CNS pathologies. Nat Neurosci 25: 876-86.
5. Dvir-Szternfeld R, Castellani G, Arad M, Cahalon L, Colaiuta SP, Keren-Shaul H, Croese T, Burgaletto
C, Baruch K, Ulland T, Colonna M, Weiner A, Amit I, Schwartz M. 2022. Alzheimer’s disease
modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in
mouse model of amyloidosis. Nature Aging 2: 60-73 (citations:17).
6. Ben-Yehuda H, Arad M, Peralta Ramos JM, Sharon E, Castellani G, Ferrera S, Cahalon L, Colaiuta SP,
Salame TM, Schwartz M. 2021. Key role of the CCR2-CCL2 axis in disease modification in a mouse
model of tauopathy. Mol Neurodegeneration 16: 39. (citations:20).
7. Cohen M, Giladi A, Raposo C, Zada M, Li B, Ruckh J, Deczkowska A, Mohar B, Shechter R, Lichtenstein
RG, Amit I, Schwartz M. 2021. Meningeal lymphoid structures are activated under acute and chronic
spinal cord pathologies. Life Sci Alliance 4: e202000907.
8. Habib N, McCabe C, Medina S, Varshavsky M, Kitsberg D, Dvir-Szternfeld R, Green G, Dionne D,
Nguyen L, Marshall JL, Chen F, Zhang F, Kaplan T, Regev A, Schwartz M. 2020. Disease- associated
astrocytes in Alzheimer’s disease and aging. Nat Neurosci 23: 701-6. (citations:617).
9. Ben-Yehuda H, Matcovitch-Natan O, Kertser A, Spinrad A, Prinz M, Amit I, Schwartz M. 2020.
Maternal Type-I interferon signaling adversely affects the microglia and the behavior of the offspring
accompanied by increased sensitivity to stress. Mol Psychiatry 25: 1050-67 (Cover page).
10. Kertser A,Baruch K, Deczkowska A,Weiner A,Croese T, Kenigsbuch M,CooperI, Tsoory M,Ben- Hamo
S, Amit I, Schwartz M. 2019. Corticosteroid signaling at the brain-immune interface impedes coping with
severe psychological stress. Sci Adv 5: eaav4111. (citations:32).
11. Rosenzweig N, Dvir-Sternfeld R, Tsitsou-Kampeli A, Keren-Shaul H, Ben-Yehuda H, Weill-Raynal P,
Cahalon L, Kertser A, Baruch K, Amit I, Weiner A, Schwartz M. 2019. PD-1/PD-L1 checkpoint blockade
harnesses monocyte-derived macrophages to combat cognitive impairment in a mouse model of tauassociated dementia. Nat Commun. 10: 465. (citations:141).
12. Deczkowska A, Matcovitch-Natan O, Tsitsou-Kampeli A, Ben-Hamo S, Dvir-Szternfeld R, Spinrad A,
Singer O, David E, Winter RD, Smith KL, Kertser A, Baruch K, Rosenzweig N, Terem A, Prinz M,
Villeda S, Citri A, Amit I, Schwartz M. 2017. Mef2C restrains the microglial inflammatory response and
is lost in brain ageing in an IFN-I-dependent manner. Nat Commun 8: 717. (citations:212).
13. Cohen M, Ben-Yehuda H, Porat Z, Raposo C, Gordon S, Schwartz M. 2017. Newly formed endothelial
2
cells regulate myeloid cell activity following spinal cord injury via expression of CD200 ligand. J
Neurosci 37: 972-85.

said Pournaghash-tehrani | Neuroscience | Best Faculty Award

Posted on by sciencefather

Dr. said Pournaghash-tehrani | Neuroscience | Best Faculty Award

 

Profile

  • Googlescholar
  • Researchgate

Education

Said Pournaghash-Tehrani earned his Doctor of Philosophy in Psychology in 1993 from The American University in Washington, D.C., where he also completed his Master of Arts in Psychology in 1990. He holds a Bachelor of Science in Distributive Science from the same institution, which he obtained in 1986. Fluent in English and German, he also has familiarity with French. He can be reached via email at spournaghash@yahoo.com or by telephone at 011-98-09122074388.

Work experience
  • Said Pournaghash-Tehrani has extensive academic and research experience in psychology. He served as a Research Associate in 2001 at the Department of Pharmacology and Experimental Therapeutics, Loyola University’s Stritch School of Medicine in Chicago, Illinois. In 2002, he took a sabbatical as a researcher at the Department of Psychology, Carleton University in Ottawa, Canada, focusing on cross-cultural studies related to Iranian attitudes towards the West. Since 2002, he has been an Assistant Professor in the Department of Psychology at Tehran University, having previously held the same position at Azzahra University in Tehran from 1996 to 2001. Additionally, he was a member of the Scientific Council on Energy and Economic Studies at the Institute for International and Political Studies (IPIS) from 1998 to 2000, where he also worked as a political researcher. His early academic career included serving as a Teaching and Research Assistant at The American University’s Department of Psychology from 1987 to 1990, where he contributed to courses such as Introduction to Psychology, Neuroscience Seminar, Psychopharmacology, Neuropsychology, Biological Basis of Behavior, and Learning and Behavior.

Books

–Fundamentals of Clinical Psychopharmacology, (2007); Samt Publications
-Drugs and Behavior, (2004); Samt Publications.
-Physiological Psychology, Tehran University Publication.
-Intimacy; Alzahra University Publication.
-Theories of Addiction, Alzahra University Publication.

Conference Presentations

Said Pournaghash-Tehrani has contributed extensively to neuroscience and psychology research, presenting his findings at prestigious conferences such as the Society for Neuroscience and the Eastern Psychological Association. His work has focused on drug discrimination learning, conditioned taste aversion, and the effects of opioids and their antagonists. In 1987, he co-authored studies assessing the discriminative stimulus properties of naloxone and the failure of cholecystokinin to counteract morphine sulfate’s effects. His later research explored the antagonism of morphine stimuli, the role of buprenorphine in opiate-naive and dependent animals, and the impact of RO15-4513 on ethanol-induced taste aversion. He has collaborated with notable researchers, including A.L. Riley, contributing to investigations on diazepam exposure and behavioral toxicology. His presentations in New Orleans, Washington, D.C., Boston, and other major research venues highlight his significant role in advancing psychopharmacology and behavioral neuroscience.

Publication

Marcelo Luis Berthier | Neuroscience| Best Researcher Award

Posted on by sciencefather

Prof. Marcelo Luis Berthier | Neuroscience| Best Researcher Award

 

Unversidad de Málaga, Spain

Profile

Education

Marcelo Luis Berthier obtained his degree in Medicine (1972-1976) and completed residency training in Neurosurgery (1977-1980), later specializing in Neurology (1980). He served as a staff neurologist at the Institute of Neurological Research, FLENI, Buenos Aires, Argentina (1980-1989), before becoming a research fellow in the Department of Neurology at Clinic Hospital of Barcelona, Spain (1989-1990). From 1991 to 2000, he was a staff neurologist and physician in charge of the Behavioural Neurology Unit at the Clinic University Hospital of Malaga. He earned a PhD in Neuroscience (cum laude) from the University of Malaga and coordinated the Group of Behavioural Neurology and Dementia of the Spanish Neurological Society (2004-2006). In 2004, he founded and directed the Unit of Cognitive Neurology and Aphasia at the Centro de Investigaciones Médico-Sanitarias, University of Malaga, leading it until 2023. Additionally, he served as the director of the Consolidated Research Group on Cognitive Neuroscience: Aphasia and Related Disorders (UNCA, C-12) at the Instituto de Investigación Biomédica de Málaga (IBIMA – Plataforma BIONAND).

Work experience

Dr. Marcelo L. Berthier Torres has led and contributed to several groundbreaking research projects in cognitive neurology and aphasia. As a co-investigator, he participated in the Telerehabilitation in Aphasia project (2021-2023), which evaluated the effectiveness of telerehabilitation compared to face-to-face therapy and identified predictive biomarkers of response, funded by the Junta de Andalucía. He also served as the principal investigator for a study on the efficacy of combined treatment with donepezil, intensive rehabilitation, and transcranial direct current stimulation in chronic post-stroke aphasia (2016-2019), funded by the Instituto de Salud Carlos III. Additionally, he has contributed to the Proyectos de Generación de Conocimiento “Frontera”, an initiative under the FEDER Andalucía 2014-2020 program, which investigates brain biomarkers for individualized treatment approaches in chronic post-stroke aphasia

Areas of Research

Dr. Marcelo L. Berthier Torres has made significant contributions to the treatment of post-stroke aphasia and speech-language disorders. He conducted the first open-label and randomized, placebo-controlled, double-blind trials investigating the use of cognitive-enhancing drugs (donepezil and memantine) alone and in combination with standard aphasia therapy or intensive language-action therapy (ILAT) in chronic post-stroke aphasia. His pioneering studies stimulated international research on aphasia pharmacotherapy, leading to clinical translation. Today, donepezil and memantine, alone or combined with therapy, are widely used off-label for post-stroke aphasia and language disturbances associated with neurodegenerative disorders like Alzheimer’s disease and primary progressive aphasia.

Publication

  • Revisiting the boundaries of different altered accents profiles

    Cortex
    2025-03 | Journal article
    DOI: 10.1016/j.cortex.2025.01.001
    CONTRIBUTORS: Marcelo L. Berthier; Ignacio Moreno-Torres; Jo Verhoeven; Guadalupe Dávila

  • Turning the Spotlight to Cholinergic Pharmacotherapy of the Human Language System

    CNS Drugs
    2023-07 | Journal article
    DOI: 10.1007/s40263-023-01017-4
    CONTRIBUTORS: Guadalupe Dávila; María José Torres-Prioris; Diana López-Barroso; Marcelo L. Berthier

  • Pharmacotherapy for post-stroke aphasia: what are the options?

    Expert Opinion on Pharmacotherapy
    2023-07-24 | Journal article
    DOI: 10.1080/14656566.2023.2221382
    CONTRIBUTORS: Marcelo L. Berthier; Guadalupe Dávila

  • Brain structural and functional correlates of the heterogenous progression of mixed transcortical aphasia

    Brain Structure and Function
    2023-05-31 | Journal article
    DOI: 10.1007/s00429-023-02655-6
    CONTRIBUTORS: Diana López-Barroso; José Paredes-Pacheco; María José Torres-Prioris; Guadalupe Dávila; Marcelo L. Berthier

  • Controlling the past, owning the present, and future: cholinergic modulation decreases semantic perseverations in a person with post-stroke aphasia

    Aphasiology
    2022-11-02 | Journal article
    DOI: 10.1080/02687038.2021.1957082
    CONTRIBUTORS: Marcelo L. Berthier; Daniel Santana-Moreno; Álvaro Beltrán-Corbellini; Juan C. Criado-Álamo; Lisa Edelkraut; Diana López-Barroso; Guadalupe Dávila; María José Torres-Prioris